RxDoctor Payments Data

Muhammad Arif, MD

Interventional Pain Medicine · Arlington, TXNPI 1952561631

Payments from drug & device makers

$3,813in general payments, 2019–2025

Across 113 payments — averaging $33.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$1K
  • Abbott$699
  • Tersera Therapeutics LLC$632
  • Scilex Pharmaceuticals Inc.$223
  • Forte Bio-pharma LLC$173
  • Boston Scientific$108
  • plus $684 from 14 others

What the payments were for

  • Travel & lodging$74319%
  • Food & beverage$2,89476%
  • Education$1775%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,813 in reported general payments places this provider in the 35th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$126,857
Medicare patients
250
Services billed
1,932

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,479$41,284
Nucynta ErTapentadol Hcl19$18,435
Xtampza ErOxycodone Myristate20$16,018
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen254$7,233
OxycontinOxycodone Hcl12$6,587
Morphine Sulfate ErMorphine Sulfate153$3,102
Morphine Sulfate59$1,231
Pregabalin47$1,046
Methadone Hcl53$888
Gabapentin77$769
Acetaminophen-CodeineAcetaminophen With Codeine29$495
Hydromorphone Hcl20$494
Buprenorphine Hcl39$467
Oxycodone Hcl43$426
Tizanidine Hcl41$324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er$13$34,45339 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →